Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.58B |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.43B |
| 3 |
Boeing
BA
|
+$283M |
| 4 |
CrowdStrike
CRWD
|
+$251M |
| 5 |
Coinbase
COIN
|
+$235M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$845M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$837M |
| 3 |
Broadcom
AVGO
|
+$691M |
| 4 |
NVIDIA
NVDA
|
+$662M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$660M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 93.75% |
| 2 | Technology | 1.85% |
| 3 | Consumer Discretionary | 1.02% |
| 4 | Financials | 0.76% |
| 5 | Communication Services | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
11476
CALL
Aclaris Therapeutics
ACRS
$907M
| $31.2K | ﹤0.01% |
27,100
+7,900
| +41% | +$9.69K |
|
11477
CALL
Taysha Gene Therapies
TSHA
$1.94B
| $31.2K | ﹤0.01% |
15,500
-34,000
| -69% | -$74.6K |
|
|
ADAP
11478
CALL
DELISTED
Adaptimmune Therapeutics
ADAP
| $31.1K | ﹤0.01% |
32,700
+21,000
| +179% | +$23.8K |
|
|
TAIT
11479
DELISTED
Taitron Components
TAIT
| $31K | ﹤0.01% |
+10,667
| New | +$30.5K |
|
|
TALK
11480
PUT
DELISTED
Talkspace
TALK
| $30.7K | ﹤0.01% |
+14,700
| New | +$28.7K |
|
11481
CALL
AbCellera Biologics
ABCL
$4.02B
| $30.7K | ﹤0.01% |
11,800
-51,700
| -81% | -$143K |
|
|
SOL
11482
PUT
DELISTED
Emeren Group
SOL
| $30.5K | ﹤0.01% |
+11,300
| New | +$21K |
|
|
IVA
11483
Inventiva
IVA
$1.16B
| $30.2K | ﹤0.01% |
+16,327
| New | +$38.2K |
|
11484
System1
SST
$16.2M
| $29.9K | ﹤0.01% |
2,667
-5,680
| -68% | -$72.9K |
|
11485
CALL
Ring Energy
REI
$383M
| $29.8K | ﹤0.01% |
18,600
-22,500
| -55% | -$40.2K |
|
|
BCLI
11486
CALL
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $29.3K | ﹤0.01% |
8,493
-120
| -1% | -$566 |
|
11487
BuzzFeed
BZFD
$92.5M
| $29.2K | ﹤0.01% |
10,968
-23,235
| -68% | -$61.9K |
|
11488
Codere Online Luxembourg Warrants
CDROW
| $29.1K | ﹤0.01% |
+29,401
| New | +$29.6K |
|
11489
Research Solutions
RSSS
$73.9M
| $28.8K | ﹤0.01% |
+10,562
| New | +$28.4K |
|
|
UBX
11490
CALL
DELISTED
Unity Biotechnology
UBX
| $28.8K | ﹤0.01% |
19,600
-8,300
| -30% | -$12.2K |
|
11491
Fortress Biotech
FBIO
$93.4M
| $28.7K | ﹤0.01% |
19,862
+1,011
| +5% | +$1.93K |
|
|
RVPH
11492
PUT
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $28.7K | ﹤0.01% |
995
-785
| -44% | -$17.4K |
|
11493
PUT
ProQR Therapeutics
PRQR
$327M
| $28.4K | ﹤0.01% |
+15,600
| New | +$29.3K |
|
11494
Fuel Tech
FTEK
$45.6M
| $28.4K | ﹤0.01% |
+27,011
| New | +$27.7K |
|
11495
Nexalin Technology
NXL
$6.54M
| $28.4K | ﹤0.01% |
+42,383
| New | +$43.7K |
|
|
NB
11496
PUT
NioCorp Developments
NB
$636M
| $28.3K | ﹤0.01% |
13,000
+2,600
| +25% | +$4.77K |
|
11497
Alzamend Neuro
ALZN
$8.06M
| $28.1K | ﹤0.01% |
+1,845
| New | +$48.3K |
|
11498
PUT
Dragonfly Energy
DFLI
$17.1M
| $28K | ﹤0.01% |
588
+191
| +48% | +$11.4K |
|
|
ICAD
11499
DELISTED
iCAD Inc
ICAD
| $28K | ﹤0.01% |
17,901
-53,199
| -75% | -$76.3K |
|
|
SLI
11500
PUT
Standard Lithium
SLI
$652M
| $28K | ﹤0.01% |
17,400
-5,500
| -24% | -$7.08K |
|
Similar funds
Jeff Yass's Q3 2024 Portfolio in Review
As of Q3 2024, Jeff Yass held 13,475 positions worth $572B, up 6.6% from $537B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Jeff Yass's Q3 2024 filing shows 1,572 new, 5,247 increased, 4,924 reduced and 1,625 closed positions. Its largest new stake was Camtek: 408,771 shares worth $32.6M. The largest sale was Apple, an estimated $845M.
By sector, the portfolio is most concentrated in Miscellaneous at 94% of assets, up from 93% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q3 2024 buy was Camtek: 408,771 shares worth $32.6M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q3 2024, an estimated $2.58B increase.
- Jeff Yass's biggest Q3 2024 reduction was Apple, cutting an estimated $845M.
- Jeff Yass fully exited iShares Convertible Bond ETF in Q3 2024, selling an estimated $80.5M.
- Jeff Yass's ten largest holdings make up 25% of its $572B portfolio in Q3 2024.
- Jeff Yass opened 1,572 new positions and closed 1,625 in Q3 2024.
- Jeff Yass's portfolio value rose 6.6% quarter-over-quarter to $572B.
Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.